Roche Holding AG said a multiple sclerosis drug showed it could work for most forms of the disease in two late-stage trials, ...

Aging and shifting hormone levels influence how MS changes over time, and the overlap of these factors during midlife can ...

Roche has reported wins for its BTK inhibitor fenebrutinib in a pair of phase 3 studies across two multiple sclerosis (MS) populations. One victory was based on the finding that the candidate was ...

Multiple sclerosis (MS) is one of the most common autoimmune diseases affecting the brain and spinal cord, with 2.9 million ...

“Identifying the causes and risk factors of MS and substantiating the effectiveness of certain interventions are both crucial ...

Explore how the Veteran Affairs (VA) MS Centers of Excellence enhance veteran care through a hub-and-spoke model, telehealth, and groundbreaking research.

Fenebrutinib met primary goals in two late-stage trials for the treatment of two different forms of multiple sclerosis.

Roche (OTCQX:RHHBY) shares closed ~4% higher in Europe on Monday as the maker of Ocrevus multiple sclerosis therapy announced ...

A study using wearable scanning technology has revealed how brain function differs in people with multiple sclerosis (MS). It ...